Evidence map›Paper›PMID 36201148›Full record

ReviewCEN case reports2023

Marked reduction of proteinuria after removal of a growth hormone-producing pituitary adenoma in a patient with focal segmental glomerulosclerosis: a case report and literature review.

Shizuka Ishigaki, Yuji Oe, Kei Omata, Yoshikiyo Ono, Yuta Tezuka, Ryo Morimoto, Shun Watanabe, Hiroyasu Nishioka, Fumitoshi Satoh, Mai Yoshida and 8 more

Open access · greenAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in CEN case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Shizuka IshigakiSchool of Medicine, Tohoku University, Sendai, 980-8574, Japan.
Yuji OeDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan. yuji-oe@med.tohoku.ac.jp.ORCID 0000-0001-8558-8832
Kei OmataDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Yoshikiyo OnoDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Yuta TezukaDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Ryo MorimotoDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Shun WatanabeDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Hiroyasu NishiokaDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Fumitoshi SatohDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Mai YoshidaDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Rui MakinoDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Koji OkamotoDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Tasuku NagasawaDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Naoko InoshitaDepartment of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
Shozo YamadaPituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.
Hiroshi SatoEast Japan Railway Sendai Hospital, Sendai, Japan.
Sadayoshi ItoKatta General Hospital, Shiroishi, Japan.
Mariko MiyazakiDivision of Nephrology, Endocrinology, and Vascular Medicine (Current Name is Division of Nephrology, Rheumatology and Endocrinology), Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Tohoku University · JPEast Japan Railway (Japan) · JPMaruyama Memorial General Hospital · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal segmental glomerulosclerosis is a rare complication of acromegaly. A 74-year-old man was found to have acromegaly features such as enlargement of the forehead, nose, and hands. Laboratory tests showed a urine protein/creatinine ratio of 3.16 g/gCr and serum creatinine of 1.34 mg/dL. The levels of growth hormone and insulin-like growth factor I were markedly elevated, and the growth hormone level was not suppressed after 75 g oral glucose loading. Magnetic resonance imaging revealed a pituitary tumor with a diameter of 1.2 cm. Renal biopsy confirmed the diagnosis of focal segmental glomerulosclerosis. Transsphenoidal resection of the pituitary tumor led to remission of acromegaly and reduction in proteinuria highlighting the causal link between growth hormone overproduction and proteinuria. Treatment of acromegaly may be effective for acromegaly-associated focal segmental glomerulosclerosis.

Indexed as

AcromegalyGlomerulosclerosis, Focal SegmentalPituitary NeoplasmsAgedGrowth HormoneHumansMaleProteinuriaGrowth HormoneAcromegalyFocal segmental glomerulosclerosisGrowth hormoneInsulin-like growth factor-1Podocyte injury

Identifiers

PMID36201148
PMCPMC10151435
OpenAlexW4302293628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.